Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Cell Therapeutics Third Quarter Net Loss Decreases by 68% in 2010 Compared to 2009

October 28, 2010 By Bio-Medicine.Org

SEATTLE, Oct. 28 /PRNewswire-FirstCall/ — Cell Therapeutics,
Inc. (“CTI” or the “Company”) (Nasdaq and MTA: CTIC) today reported
recent accomplishments and financial results for the third quarter
ended September 30, 2010.

“We have made solid progress in controlling costs with a 52%
decrease in net operating expense and a 68% decrease in net loss
for the quarter compared to the same period last year while
strengthening the balance sheet with the recent financing,” said
James A. Bianco, M.D., Chief Executive Officer of the Company. “We
continue to advance pixantrone toward a Marketing Authorization
Application submission in the E.U. and readying the clinical trial
networks for initiating the PIX 306 follow-on pivotal clinical
study.”

Recent Highlights

Received positive opinion agreeing to the Pediatric Investigation
Plan for pixantrone from the Pediatric Committee (PDCO) of the
European Medicines Agency (EMA). Additionally, the PDCO also
recommended deferral of the initiation of the clinical studies
until after the drug receives EMA approval. Announced intention to
appeal the U.S. Food and Drug Administration’s (the “FDA”) decision
on New Drug Application (NDA) for pixantrone, which submission is
targeted for November. Submitted PIX306 follow-on pivotal study to
the newly created Division of Hematologic Products at FDA for
review. Retired all convertible debt due in 2010 The Mayo Clinic’s
clinical trial network, the North Central Cancer Treatment Group
(“NCCTG”), initiated patient enrollment in two phase II programs
conducted by the NCCTG: one clinical trial with pixantrone in
metastatic breast cancer and one clinical trial using brostallicin
in triple negative metastatic breast cancer.

For the quarter ended September 30, 2010, total net operating
expenses decreased 52% to $13.0 million compared to $27.1 million
for the same period in 2009.  The decrease was mainly due to
decreased expenses

‘/>”/>

SOURCE

Related Articles Read More >

A portrait of Ellen Roche, MIT School of Engineering associate professor
New implant design prevents scar tissue without drugs, MIT says
UMN artificial blood vessel clinical trial
Minnesota researchers awarded $3.7M grant for artificial, bioengineered blood vessel clinical trial
CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’
Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials

DeviceTalks Weekly.

August 5, 2022
DTW Medtronic's Greg Smith lays out supply chain strategies
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech